Andrew Combs - 04 Feb 2026 Form 4 Insider Report for Prelude Therapeutics Inc (PRLD)

Role: Chief Chemistry Officer
Signature: /s/ Bryant D. Lim, Attorney-in-Fact
Issuer symbol: PRLD
Transactions as of: 04 Feb 2026
Net transactions value: $0
Form type: 4
Filing time: 05 Feb 2026, 16:14:15 UTC
Previous filing: 27 Mar 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Combs Andrew	Chief Chemistry Officer	C/O PRELUDE THERAPEUTICS INCORPORATED, 175 INNOVATION BOULEVARD, WILMINGTON	/s/ Bryant D. Lim, Attorney-in-Fact	05 Feb 2026	0001825005

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PRLD	Employee Stock Option (right to buy)	Award	$0	+230,000		$0.000000	230,000	04 Feb 2026	Common Stock	230,000	$2.30	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The stock option vests as to 25% of the total shares on Feb 4, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.